

Appendix I.

Per-protocol (PP) population

The PP population consisted of all randomly assigned patients who fully complied with the inclusion and exclusion criteria, received all doses of study treatment up to Week 30, not received any prohibited therapies, and had an ACR assessment at Week 30.

For the following reason, 107 patients (54 patients from CT-P13 group, 53 patients from INX group) were excluded from all randomised population (N=606) in the PP population (N=499).

Table S6. The number (%) of patients excluded due to protocol violations.

	Number (%) of Patients		
	CT-P13 3 mg/kg (N=302)	INX 3 mg/kg (N=304)	Total (N=606)
Misrandomisations ^[1]	0	1 (0.3)	1 (0.2)
Noncompliance with inclusion/exclusion criteria	2 (0.7)	3 (1.0)	5 (0.8)
An assessment out of window by more than 2 weeks for Dose 6	2 (0.7)	3 (1.0)	5 (0.8)
Receipt of corticosteroids	4 (1.3)	5 (1.6)	9 (1.5)
Patients who did not receive all doses of study treatment up to Week 30	48 (15.9) ^a	44 (14.5) ^a	92 (15.2)
– Patients who did not have an ACR assessment at Week 30	45 (14.9)	43 (14.1)	88 (14.5)
Patients who discontinued or reduced their methotrexate dose for more than 2 consecutive weeks up to Week 30	2 (0.7) ^b	1 (0.3)	3 (0.5)

Note: PP = per-protocol population.

^[1] Misrandomisations defined as patients who received the opposite treatment to which they were assigned at any point during the study.

- a. Two patients from CT-P13 group and a patient from INX group due to noncompliance with inclusion/exclusion criteria and 2 patients from both groups due to receipt of corticosteroids were already excluded from the PP population. One patient in the CT-P13 group skipped Dose 4 and received Dose 5 and 6, therefore considered that did not receive all doses of study treatment up to Week 30.
- b. One patient was already excluded from PP due receipt of corticosteroids.